Characterization of graft-versus-leukemia responses in patients treated for advanced chronic lymphocytic leukemia with donor lymphocyte infusions after in vitro T-cell depleted allogeneic stem cell transplantation following reduced-intensity conditioning [16]

Leukemia

Volumn 21, Issue 12, 2007, Pages 2569-2574

  Hoogendoorn, M ^a   Jedema, I ^a   Barge, R M Y ^a   van Luxemburg Heijs, S A P ^a   Beaumont, F ^a   Marijt, E W A ^a   Willemze, R ^a   Falkenburg, J H F ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CD3 ANTIGEN; FLUDARABINE; THYMOCYTE ANTIBODY;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DONOR LYMPHOCYTE INFUSION; FEMALE; FLOW CYTOMETRY; FOLLOW UP; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HLA MATCHING; HUMAN; IMMUNE RESPONSE; INFECTIOUS COMPLICATION; LETTER; MALE; MYELOABLATIVE CONDITIONING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; SKIN DISEASE; T CELL DEPLETION; TREATMENT RESPONSE;

EID: 36348945154     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404838     Document Type: Letter

References (8)

1. Schetelig J, Thiede C, Bornhauser M, Schwerdtfeger R, Kiehl M, Beyer J et al. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: The Cooperative German Transplant Study Group. J Clin Oncol 2003; 21: 2747-2753.
2. Sorror ML, Maris MB, Sandmaier BM, Storer BE, Stuart MJ, Hegenbart U et al. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 3819-3829.
3. Delgado J, Thomson K, Russell N, Ewing J, Stewart W, Cook G et al. Results of alemtuzumab-based reduced intensity allogeneic transplantation for chronic lymphocytic leukemia: A British Society of Blood and Marrow Transplantation Study. Blood 2006; 107: 1724-1730.
4. Peggs KS, Thomson K, Hart DP, Geary J, Morris EC, Yong K et al. Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: Toxicity, chimerism, and disease responses. Blood 2004; 103: 1548-1556.
5. Barge RM, Osanto S, Marijt WA, Starrenburg CW, Fibbe WE, Nortier JW et al. Minimal GVHD following in-vitro T-cell-depleted allogeneic stem cell transplantation with reduced-intensity conditioning allowing subsequent infusions of donor lymphocytes in patients with hematological malignancies and solid tumors. Exp Hematol 2003; 31: 865-872.
6. Hoogendoorn M, Olde Wolbers J, Smit WM, Schaafsma MR, Barge RM, Willemze R et al. Generation of B-cell chronic lymphocytic leukemia (B-CLL)-reactive T-cell lines and clones from HLA class I-matched donors using modified B-CLL cells as stimulators: Implications for adoptive immunotherapy. Leukemia 2004; 18: 1278-1287.
7. Jedema I, Meij P, Steeneveld E, Hoogendoorn M, Nijmeijer BA, van de MM et al. Early detection and rapid isolation of leukemia-reactive donor T cells for adoptive transfer using the IFN-gamma secretion assay. Clin Cancer Res 2007; 13: 636-643.
8. Moreno C, Villamor N, Colomer D, Esteve J, Martino R, Nomdedeu J et al. Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 3433-3438.